OTLK

Outlook Therapeutics Inc. (OTLK) | Rumor.io

Outlook Therapeutics

OTLK

Attention (50-day avg)0.01%

Attention rank (50-day avg)#348

Bullish sentiment (50-day avg)73%

Price to earnings ratio0.57

Market capitalization151.2M

Earnings per share-0.7

Dividend yield (TTM)—

Revenue (annual)1.4M

Net income (annual)-62.4M

Social

What share of all stock conversation is about OTLK?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% -0.01	0.01% 0	0.01% -0.01	0.01% +0

Sep 29

The FDA approval of LYTENAVA was on July 24, and the first opportunity to apply for a permanent J-Code is the October 2026 cycle.
The company's commercialization efforts and execution are crucial for justifying a valuation above $1B, and the market is currently unwilling to assign this valuation.
Outlook Therapeutics' team is rebuilding with a strong focus on commercialization and execution, and the company has four days to notify shareholders of non-compliance before applying for a Code J designation.

Generated by AI

Sentiment

Of the messages about OTLK that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	66.67% +23.03	70.99% -10.63	80% +10.33	85.18% -0.81
Bearish	33.33% -23.03	29.01% +10.63	20% -10.33	14.82% +0.81

Bullish· Aug 25

The company is working to execute pricing and getting out of the gate ASAP to avoid further dilution, which could lead to a significant increase in value.
The sale of additional vials in the UK is resulting in a price surge, and further sales could lead to a significant increase in momentum.
The company has a huge marketing opportunity worldwide, with the potential for estimated $8 billion in revenue in a few years, making it a safe stock to hold for retirement.

Bearish· Aug 18

The company's management is struggling to prove the commercial story, with uncertain reimbursement, physician adoption, and competition from cheap off-label Avastin.
The recent financing added a large number of shares and warrants, creating a potential overhang around $1.10 and increasing the risk of dilution.
The stock has broken below key support levels, with the $0.60 price point being a critical level that, if broken, could lead to further declines and potentially test lower levels.

Generated by AI

Topics

Of the messages about OTLK that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	86.11%	43.02%	21.29%
Technical Analysis	—	11.11%	21.37%	21.47%
Analysts	—	0%	20.8%	28.16%
Earnings	—	0%	0%	2.89%
Macro	—	0%	13.11%	24.73%
Controversies	—	2.78%	1.71%	1.47%

Analysts· May 16

Oppenheimer initiated coverage of Outlook Therapeutics (OTLK) with an outperform rating and a $12 price target.
The price target of $12 is a significant premium to the current price, making it a worthwhile risk for investors.
Two analysts, Ascendiant and Oppenheimer, have issued buy ratings for OTLK with average price targets of $8 and $12, respectively.

Announcements· Aug 14

Outlook Therapeutics, Inc. has secured FDA approval for LYTENAVA, a bevacizumab-based treatment for wet AMD, and plans to launch it in the US by the end of 2026.
The company expects to exceed $500 million in annual US sales by 2030 and has guided for $50-75 million in total net revenue during the first 12 months post-US launch.
Outlook Therapeutics has completed a public offering of 55.56 million shares at $0.99 each, generating approximately $55 million in gross proceeds to support commercialization and working capital.

Technical Analysis· May 28

$OTLK broke previous 4HR high at $0.5969, with key levels to hit at $0.6432 and $0.7250.
Strong bullish momentum is confirmed by massive volume, with resistance at $0.7932 and support at $0.6103.
$OTLK has a cup and handle pattern with a $3.X target, and a key resistance zone that is currently being tested.

Generated by AI

Community

Of the messages about OTLK, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	87.84%	82.95%	74.91%	52.6%
Newcomers	12.16%	17.05%	25.09%	47.4%

Regulars· Sep 29

The permanent J-Code application for LYTENAVA is expected to be submitted in the October 2026 cycle, with a potential effective date later in the year, while interim billing mechanisms can be used in the meantime.
The valuation of Outlook Therapeutics, Inc. may increase if it demonstrates sufficient commercial penetration, potentially justifying a valuation above $1B, but the market is currently unwilling to assign this valuation without seeing execution.
The company's focus on commercialization and execution is being rebuilt, with a strong emphasis on sales, and some participants are optimistic about its potential, considering it a "sleeping giant" that may not be ready for institutional capital until its stock price reaches $6.00.

Newcomers· Sep 24

The company has a potential catalyst coming up with the permanent HCPCS code application by October 1, which could lead to reimbursement and commercial launch.
The U.S. retinal injection market is estimated at 3.7 million injections annually, and capturing just 1.9% of the Avastin volume could generate approximately $5.1 million in revenue for the company in October-December.
The consensus rating is BUY, with high and low targets set at $9 and $2 respectively, and the company is expected to report its first fiscal quarter results in mid- or late February 2027.

Generated by AI

Fireside chat featuring Bob Jahr, Chief Executive Officer, and H.C. Wainwright Managing Director & Senior Biotechnology Equity Research Analyst Access the video webcast here ISELIN, N.J., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that its pre-recorded fireside chat from the H.C. W

19d agoYahoo Finance

Outlook Therapeutics CEO discusses LYTENAVA commercial launch

19d agoInvesting.com

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment

Access the segment here ISELIN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that Bob Jahr, Chief Executive Officer, recently participated in a Virtual Investor CEO Connect segment discussing the significance of the FDA approval of LYTENAVA and the Company’s plans for its U.S.

19d agoYahoo Finance Singapore

Outlook Therapeutics Announces CFO Transition and Board Change

Detailed price information for Outlook Therapeutics Inc (OTLK-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Outlook Therapeutics Appoints Kevin Lundquist as CFO

Outlook Therapeutics (OTLK) said late Thursday it appointed Kevin Lundquist as chief financial offic

1mo agoYahoo Finance

Also Discussed

Investors talking about OTLK also mention

#	Name	Attention
1	Eltek Ltd.ELTK	0%new
2	OBLN - Obalon Therapeutics, Inc.	——
3	Aspire Biopharma Holdings, Inc.ASBP	0%new
4	Gossamer Bio Inc.GOSS	0%+0
5	Mereo BioPharma Group plc ADRMREO	0.01%-0.01
6	vTv Therapeutics Inc. Class A Common StockVTVT	0%new
7	Legacy Education Inc.LGCY	0%new
8	Bio-Path Holdings Inc.BPTH	0%0
9	Precipio Inc.PRPO	0%0
10	Protara Therapeutics, Inc.TARA	0%0

Outlook Therapeutics Inc.

Healthcare
Biotechnology

Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology and retinal diseases. The company develops and commercializes LYTENAVA (bevacizumab-vikg, bevacizumab gamma), an ophthalmic formulation of bevacizumab designed for use in retinal indications such as wet age-related macular degeneration. Its product work centers on ONS-5010, a monoclonal antibody candidate intended to address unmet needs in the treatment of retinal vascular disorders. Outlook Therapeutics operates in the specialty eye-care segment of the pharmaceutical market, where biologic therapies are used to support vision-related conditions affecting the retina. The company’s current business is built around advancing and commercializing this ophthalmic anti-VEGF therapy across regulated markets for patients with serious retinal diseases.

Website

Location

111 S. Wood Avenue

Iselin, NJ, 08830

United States

Social

What share of all stock conversation is about OTLK?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% -0.01	0.01% 0	0.01% -0.01	0.01% +0

Sep 29

The FDA approval of LYTENAVA was on July 24, and the first opportunity to apply for a permanent J-Code is the October 2026 cycle.
The company's commercialization efforts and execution are crucial for justifying a valuation above $1B, and the market is currently unwilling to assign this valuation.
Outlook Therapeutics' team is rebuilding with a strong focus on commercialization and execution, and the company has four days to notify shareholders of non-compliance before applying for a Code J designation.

Generated by AI

Sentiment

Of the messages about OTLK that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	66.67% +23.03	70.99% -10.63	80% +10.33	85.18% -0.81
Bearish	33.33% -23.03	29.01% +10.63	20% -10.33	14.82% +0.81

Bullish· Aug 25

The company is working to execute pricing and getting out of the gate ASAP to avoid further dilution, which could lead to a significant increase in value.
The sale of additional vials in the UK is resulting in a price surge, and further sales could lead to a significant increase in momentum.
The company has a huge marketing opportunity worldwide, with the potential for estimated $8 billion in revenue in a few years, making it a safe stock to hold for retirement.

Bearish· Aug 18

The company's management is struggling to prove the commercial story, with uncertain reimbursement, physician adoption, and competition from cheap off-label Avastin.
The recent financing added a large number of shares and warrants, creating a potential overhang around $1.10 and increasing the risk of dilution.
The stock has broken below key support levels, with the $0.60 price point being a critical level that, if broken, could lead to further declines and potentially test lower levels.

Generated by AI

Topics

Of the messages about OTLK that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	86.11%	43.02%	21.29%
Technical Analysis	—	11.11%	21.37%	21.47%
Analysts	—	0%	20.8%	28.16%
Earnings	—	0%	0%	2.89%
Macro	—	0%	13.11%	24.73%
Controversies	—	2.78%	1.71%	1.47%

Analysts· May 16

Oppenheimer initiated coverage of Outlook Therapeutics (OTLK) with an outperform rating and a $12 price target.
The price target of $12 is a significant premium to the current price, making it a worthwhile risk for investors.
Two analysts, Ascendiant and Oppenheimer, have issued buy ratings for OTLK with average price targets of $8 and $12, respectively.

Announcements· Aug 14

Outlook Therapeutics, Inc. has secured FDA approval for LYTENAVA, a bevacizumab-based treatment for wet AMD, and plans to launch it in the US by the end of 2026.
The company expects to exceed $500 million in annual US sales by 2030 and has guided for $50-75 million in total net revenue during the first 12 months post-US launch.
Outlook Therapeutics has completed a public offering of 55.56 million shares at $0.99 each, generating approximately $55 million in gross proceeds to support commercialization and working capital.

Technical Analysis· May 28

$OTLK broke previous 4HR high at $0.5969, with key levels to hit at $0.6432 and $0.7250.
Strong bullish momentum is confirmed by massive volume, with resistance at $0.7932 and support at $0.6103.
$OTLK has a cup and handle pattern with a $3.X target, and a key resistance zone that is currently being tested.

Generated by AI

Community

Of the messages about OTLK, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	87.84%	82.95%	74.91%	52.6%
Newcomers	12.16%	17.05%	25.09%	47.4%

Regulars· Sep 29

The permanent J-Code application for LYTENAVA is expected to be submitted in the October 2026 cycle, with a potential effective date later in the year, while interim billing mechanisms can be used in the meantime.
The valuation of Outlook Therapeutics, Inc. may increase if it demonstrates sufficient commercial penetration, potentially justifying a valuation above $1B, but the market is currently unwilling to assign this valuation without seeing execution.
The company's focus on commercialization and execution is being rebuilt, with a strong emphasis on sales, and some participants are optimistic about its potential, considering it a "sleeping giant" that may not be ready for institutional capital until its stock price reaches $6.00.

Newcomers· Sep 24

The company has a potential catalyst coming up with the permanent HCPCS code application by October 1, which could lead to reimbursement and commercial launch.
The U.S. retinal injection market is estimated at 3.7 million injections annually, and capturing just 1.9% of the Avastin volume could generate approximately $5.1 million in revenue for the company in October-December.
The consensus rating is BUY, with high and low targets set at $9 and $2 respectively, and the company is expected to report its first fiscal quarter results in mid- or late February 2027.

Generated by AI

Outlook Therapeutics

Social

Sep 29

Bullish· Aug 25

Bearish· Aug 18

Analysts· May 16

Announcements· Aug 14

Technical Analysis· May 28

Regulars· Sep 29

Newcomers· Sep 24

Outlook Therapeutics at H.C. Wainwright: launch hinges on access

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand

Outlook Therapeutics CEO discusses LYTENAVA commercial launch

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment

Outlook Therapeutics Announces CFO Transition and Board Change

Outlook Therapeutics Appoints Kevin Lundquist as CFO

Also Discussed

Outlook Therapeutics Inc.

Company Information

Location

Outlook Therapeutics at H.C. Wainwright: launch hinges on access

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand

Outlook Therapeutics CEO discusses LYTENAVA commercial launch

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment

Outlook Therapeutics Announces CFO Transition and Board Change

Outlook Therapeutics Appoints Kevin Lundquist as CFO

Also Discussed

Social

Sep 29

Bullish· Aug 25

Bearish· Aug 18

Analysts· May 16

Announcements· Aug 14

Technical Analysis· May 28

Regulars· Sep 29

Newcomers· Sep 24